Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Consolidation After AlloSCT for Relapsed/Refractory Hodgkin Lymphoma
NCT03652441Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Nov 2019
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Cumulative Incidence of Relapse at 1 year. Started Nov 2019; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03652441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652441.